
Kevin McKernanå çã®è«æãåé€ããããšããå¢åãå± ããKevin McKernanå çããçããã«ããé¡ããããã
https://www.tandfonline.com/doi/full/10.1080/08916934.2025.2551517#abstract
Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada
ã«ããã»ãªã³ã¿ãªãªå·ç£ãã¡ã€ã¶ãŒ/ããªã³ããã¯ç€Ÿããã³ã¢ãã«ã瀟補modRNA COVID-19ã¯ã¯ãã³ã«ãããæ®çãã©ã¹ããDNAããã³SV40ããã¢ãŒã¿ãŒã»ãšã³ãã³ãµãŒé åã®å®é
Jessica Rose&Kevin McKernan
Abstract
For some of the COVID-19 vaccines, the drug substances released to market were manufactured differently than those used in clinical trials. Manufacturing nucleoside-modified mRNA (modRNA) for commercial COVID-19 vaccines relies on RNA polymerase transcription of a plasmid DNA template. Previous studies identified high levels of plasmid DNA in vials of modRNA vaccines, suggesting that the removal of residual DNA template is problematic. Therefore, we quantified the DNA load in a limited number of Pfizer-BioNTech and Moderna COVID-19 modRNA vaccine vials using two independent methods. Total DNA and specific DNA targets were quantified by Qubit fluorometry and quantitative polymerase chain reaction (qPCR), respectively on 32 vials representing 16 unique vaccine lots. RNase A treatment was used to assess the impact of RNA crosstalk in DNA fluorometry. A preliminary assessment of DNA fragment length and DNase I sensitivity were also performed. Total DNA ranged 371â1,548âng/dose and 1,130â6,280âng/dose in Pfizer and Moderna products, respectively. Specific DNA of multiple plasmid DNA targets ranged 0.22â7.28âng/dose for Pfizer, and 0.01â0.78âng/dose for Moderna. The SV40 promoter-enhancer-ori (0.25â23.72âng/dose) was only detected in Pfizer vials. Oxford Nanopore sequencing of one vial found mean and maximum DNA fragment lengths of 214âbp and 3.5âkb, respectively. These data demonstrate the presence of 1.23âÃâ108 to 1.60âÃâ1011 plasmid DNA fragments per dose encapsulated in lipid nanoparticles. Using fluorometry, total DNA in all vials tested exceeded the regulatory limit for residual DNA set by the US Food & Drug Administration (FDA) and the World Health Organization (WHO) by 36â153-fold for Pfizer and 112â627-fold for Moderna after accounting for nonspecific binding to modRNA. When tested by qPCR, all Moderna vials were within the regulatory limit, but 2/6 Pfizer lots (3 vials) exceeded the regulatory limit for the SV40 promoter-enhancer-ori by 2-fold. The presence of the SV40 promoter-enhancer element in Pfizer vials raises significant safety concerns. This study emphasizes the importance of methodological considerations when quantifying residual plasmid DNA in modRNA products, considering increased LNP transfection efficiency, and cumulative dosing presents significant and unquantified risks to human health.
COVID-19ã¯ã¯ãã³ã®ãã¡äžéšã¯ãèšåºè©Šéšã§äœ¿çšããããã®ãšã¯ç°ãªãè£œé æ¹æ³ã§åžå Žã«åºè·ãããåè¬ãçšããããŠããŸããåžè²©ãããŠããCOVID-19ã¯ã¯ãã³çšãã¯ã¬ãªã·ã修食mRNAïŒmodRNAïŒã®è£œé ã«ã¯ãRNAããªã¡ã©ãŒãŒã«ãããã©ã¹ããDNAé³åã®è»¢åãäžå¯æ¬ ã§ããå è¡ç ç©¶ã§ã¯ãmodRNAã¯ã¯ãã³ãã€ã¢ã«ããé«ã¬ãã«ã®ãã©ã¹ããDNAãæ€åºãããŠãããããã¯æ®åDNAé³åã®é€å»ãå°é£ã§ããããšã瀺åããŠããŸãã
ããã§æ¬ç ç©¶ã§ã¯ããã¡ã€ã¶ãŒã»ããªã³ããã¯ç€Ÿè£œããã³ã¢ãã«ã瀟補COVID-19 modRNAã¯ã¯ãã³ã®éãããæ°ã®ãã€ã¢ã«ã«ã€ããŠã2ã€ã®ç¬ç«ããææ³ãçšããŠDNAéãå®éããŸãããåèš16ãããã®ã¯ã¯ãã³ã«å¯Ÿå¿ãã32ãã€ã¢ã«ã«ã€ããŠãQubitèå å®éæ³ããã³å®éçããªã¡ã©ãŒãŒé£éåå¿ïŒqPCRïŒãçšããŠãããããç·DNAéãšç¹å®ã®DNAæšçãå®éããŸãããRNase AåŠçãè¡ããDNAèå å®éæ³ã«ãããRNAã®ã¯ãã¹ããŒã¯ã®åœ±é¿ãè©äŸ¡ããŸããããŸããDNAæçã®é·ããšDNase Iæåæ§ã«ã€ããŠãäºåçãªè©äŸ¡ãè¡ããŸããã
ãã®çµæãç·DNAéã¯ãã¡ã€ã¶ãŒç€Ÿè£œåã§371ã1,548 ng/doseãã¢ãã«ã瀟補åã§1,130ã6,280 ng/doseã®ç¯å²ã§ãããè€æ°ã®ãã©ã¹ããDNAæšçã®ç¹ç°çDNAéã¯ããã¡ã€ã¶ãŒç€Ÿè£œã§0.22ã7.28 ng/doseãã¢ãã«ã瀟補ã§0.01ã0.78 ng/doseã§ãããSV40ããã¢ãŒã¿ãŒ/ãšã³ãã³ãµãŒ/ãªãªãžã³ïŒ0.25ã23.72 ng/doseïŒã¯ããã¡ã€ã¶ãŒç€Ÿè£œãã€ã¢ã«ã§ã®ã¿æ€åºãããŸããã1ã€ã®ãã€ã¢ã«ããªãã¯ã¹ãã©ãŒãã»ãããã¢ã·ãŒã±ã³ã·ã³ã°ã§è§£æãããšãããDNAæçã®å¹³åé·ã¯214 bpãæå€§é·ã¯3.5 kbã§ããããããã®ããŒã¿ã¯ãè質ããç²åã«å°å ¥ããããã©ã¹ããDNAæçã1çšéããã1.23 à 10^8ã1.60 à 10^11åååšããããšã瀺ããŠããŸãã
èå å®éæ³ãçšããå ŽåãmodRNAãžã®éç¹ç°ççµåãèæ ®ããŠãã詊éšãããã¹ãŠã®ãã€ã¢ã«ã®ç·DNAéã¯ãç±³åœé£åå»è¬åå±ïŒFDAïŒããã³äžçä¿å¥æ©é¢ïŒWHOïŒãå®ããæ®çDNAã®èŠå¶å€ãè¶ ããŠããããã¡ã€ã¶ãŒç€Ÿè£œã§ã¯36ã153åãã¢ãã«ã瀟補ã§ã¯112ã627åã§ãããqPCRã§è©Šéšãããšãããã¢ãã«ã瀟補ãã€ã¢ã«ã¯ãã¹ãŠèŠå¶å€å ã§ãããããã¡ã€ã¶ãŒç€Ÿè£œãããã®6ãããäž2ãããïŒ3ãã€ã¢ã«ïŒã¯SV40ããã¢ãŒã¿ãŒ/ãšã³ãã³ãµãŒ/ãªãªãžã³ã®èŠå¶å€ã2åè¶ ããŠããŸããããã¡ã€ã¶ãŒç€Ÿè£œãã€ã¢ã«ã«SV40ããã¢ãŒã¿ãŒ/ãšã³ãã³ãµãŒèŠçŽ ãååšããããšã¯ãé倧ãªå®å šäžã®æžå¿µãåŒãèµ·ãããŸãã
æ¬ç ç©¶ã¯ãmodRNA補åäžã®æ®çãã©ã¹ããDNAãå®éããéã®ææ³äžã®èæ ®ç¹ã®éèŠæ§ã匷調ãããšãšãã«ãLNPã®ãã©ã³ã¹ãã§ã¯ã·ã§ã³å¹çã®åäžãçŽ¯ç©æäžãããã®å¥åº·ã«é倧ãã€æªè§£æãªãªã¹ã¯ãããããããšã瀺åããŠããŸãã
When tested by qPCR, all Moderna vials were within the regulatory limit, but 2/6 Pfizer lots (3 vials) exceeded the regulatory limit for the SV40 promoter-enhancer-ori by 2-fold.ã
â
ãã®è±æã®ãSV40 promoter-enhancer-oriãã®ãoriããšã¯ïŒ
ããªãªãžã³ïŒoriginïŒããšã¯ãéºäŒåå·¥åŠã«ãããŠãDNAè€è£œéå§ç¹ãæããŸãã
ããã¯ããã©ã¹ããDNAã®ãããªç°ç¶DNAã现èå ã§å¢æ®ããããã«äžå¯æ¬ ãªé åã§ããã€ãŸããDNAããªã¡ã©ãŒãŒãããããDNAã®ã³ããŒãè€è£œãå§ããŸããSV40ããã¢ãŒã¿ãŒ/ãšã³ãã³ãµãŒ/ãªãªãžã³é åã¯ããŠã€ã«ã¹ç±æ¥ã®åŒ·åãªéºäŒåçºçŸèª¿ç¯é åã§ãçæ žçްèå ã§å¹ççã«éºäŒåãå¢ããããã«åºãå©çšãããŠããŸãã
ãã®æèã§ã®ããªãªãžã³ãã¯ããã®é
åããã©ã¹ããDNAã®è€è£œãå¯èœã«ããæ©èœãæã€ããšãæå³ããŠããŸããèŠå¶å€ãè¶
ãããšããããšã¯ããã®DNAã现èå
ã§èªå·±å¢æ®ããäºæãã¬åœ±é¿ãåãŒãå¯èœæ§ãé«ãŸããããå®å
šæ§ã®èгç¹ããåé¡èŠãããŠããŸãã
Please link this article to your tweets about this so your comments get pulled in my Almetrics.
â Kevin McKernan (@Kevin_McKernan) September 19, 2025
They only scrape tweets that contain the primary link.https://t.co/UCkQ3ZcO9n
ãã®æçš¿ãããªãã®ãã€ãŒãã«ãªã³ã¯ããŠãã ãããããããã°ãç§ã®Almetricsã«ããªãã®ã³ã¡ã³ããåã蟌ãŸããŸããAlmetricsã¯ãã¡ã€ã³ã®ãªã³ã¯ãå«ããã€ãŒãããã¹ã¯ã¬ã€ãã³ã°ããªãã®ã§ã
Kevin McKernanå çã¯ãçããããã€ãŒãããéã«ããã®è«æã®URLïŒhttps://www.tandfonline.com/doi/full/10.1080/08916934.2025.2551517#abstractïŒãå¿ ãå«ããŠã»ãããšé Œãã§ããŸãã
ããããããšã§ãAlmetricsãšããåæããŒã«ããçããã®ãã€ãŒããããã®è«æã«é¢ããè°è«ããšããŠèªèãã远跡ããããã ã
補è¬äŒç€Ÿãããè³è³ããåãåã£ãŠããè ã£ãé£äžãå± ãããã®é£äžã¯ä»ãKevin McKernanå çãã®è«æãæ€åãããããšæèºããŠããã®ã ãæ¬ä»¶è«æã®URLããçããã®Tweetã®äžã«æžã蟌ã¿ãæ¡æ£ããŠã»ããã